Abstract
Childhood obesity represents a significant global health concern and identifying risk factors is crucial for developing intervention programs. Many 'omics' factors associated with the risk of developing obesity have been identified, including genomic, microbiomic, and epigenomic factors. Here, using a sample of 48 infants, we investigated how the methylation profiles in cord blood and placenta at birth were associated with weight outcomes (specifically, conditional weight gain, body mass index, and weight-for-length ratio) at age six months. We characterized genome-wide DNA methylation profiles using the Illumina Infinium MethylationEpic chip, and incorporated information on child and maternal health, and various environmental factors into the analysis. We used regression analysis to identify genes with methylation profiles most predictive of infant weight outcomes, finding a total of 23 relevant genes in cord blood and 10 in placenta. Notably, in cord blood, the methylation profiles of three genes (PLIN4, UBE2F, and PPP1R16B) were associated with all three weight outcomes, which are also associated with weight outcomes in an independent cohort suggesting a strong relationship with weight trajectories in the first six months after birth. Additionally, we developed a Methylation Risk Score (MRS) that could be used to identify children most at risk for developing childhood obesity. While many of the genes identified by our analysis have been associated with weight-related traits (e.g., glucose metabolism, BMI, or hip-to-waist ratio) in previous genome-wide association and variant studies, our analysis implicated several others, whose involvement in the obesity phenotype should be evaluated in future functional investigations.
Introduction
Obesity is a major public health challenge, yet early-life prediction remains difficult. Traditional Genome-Wide Association Studies (GWAS) explain only a small fraction of the variation in Body Mass Index (BMI), leading to the concept of "missing heritability." Epigenetics, particularly DNA methylation, offers a potential bridge. Unlike the static genetic code, the epigenome is modifiable by environmental factors and can influence gene expression. This study investigates whether epigenetic markers present at birth can predict growth trajectories in the first six months of life, a critical period for metabolic programming.
Methods
The study utilized the "SIBSIGHT" cohort, following 48 infants. Researchers collected cord blood and placenta tissue at birth. Epigenetic profiling was performed using the Illumina Infinium MethylationEPIC chip, measuring over 575,000 CpG sites. To manage the high-dimensional data, signals were averaged across gene bodies for approximately 20,000 genes.
LASSO (Least Absolute Shrinkage and Selection Operator) regression was employed to identify genes predictive of three weight outcomes at six months: Conditional Weight Gain (CWG), BMI, and weight-for-length ratio. These findings were used to develop a Methylation Risk Score (MRS). The results were further validated using the PROGRESS cohort, an independent dataset of 1,001 individuals from Mexico City.
Results
Tissue-Specific Methylation Profiles
Analysis revealed significant differences between the two tissue types. Cord blood provided a clearer signal for weight outcomes compared to the placenta. The placenta exhibited highly heterogeneous methylation profiles, likely due to its complex mix of cell types, which complicates the identification of consistent biomarkers.
Identification of Key Predictive Genes
The study identified 23 relevant genes in cord blood and 10 in the placenta associated with infant growth. Three specific genes in cord blood—PLIN4, UBE2F, and PPP1R16B—emerged as "master predictors," showing significant associations across all three weight outcomes.
- PLIN4: Involved in lipid storage; higher methylation was associated with increased weight.
- UBE2F: Linked to protein degradation and previously associated with childhood BMI; higher methylation was associated with increased weight.
- PPP1R16B: Plays a role in endothelial stability and linked to diabetes; higher methylation was associated with decreased weight.
Predictive Performance of the Methylation Risk Score
The cord blood MRS for CWG demonstrated exceptional predictive power in the discovery cohort, with an adjusted R-squared of 0.874 ($p \le 2.2 \times 10^{-16}$). Furthermore, the MRS calculated at birth remained significantly correlated with weight outcomes at one and two years of age, suggesting its potential as a long-term biomarker.
Discussion and Limitations
While promising, the study has several limitations. The discovery cohort size (n=48) is small for 'omics' research, necessitating larger validation studies. Additionally, the MRS did not transfer perfectly to the PROGRESS cohort, highlighting the influence of ethnic and environmental factors on epigenetic markers. The gene-level analysis may also have overlooked high-impact individual CpG sites. Finally, as an observational study, these findings demonstrate correlation rather than causation; future functional studies are required to determine the biological mechanisms driving these associations.
Summary updated